Molecular Exploitation of Apoptosis Pathways in Prostate Cancer, Molecular Exploitation of Apoptosis Pathways in Prostate Cancer

Natasha Kyprianou,

ISBN 10: 1848164491 / ISBN 13: 9781848164499

Published by Imperial College Press, 2011

About this Item

This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Seller Inventory # ABNR-144965

Bibliographic Details

• Title: Molecular Exploitation of Apoptosis Pathways in Prostate Cancer, Molecular Exploitation of Apoptosis Pathways in Prostate Cancer
• Publisher: Imperial College Press
• Publication Date: 2011
• Language: English
• ISBN 10: 1848164491
• ISBN 13: 9781848164499
• Binding: Hardcover
• Condition: New

About this title

Synopsis

This book focuses on the functional significance of targeting apoptosis for the treatment of prostate cancer. New concepts on the challenges relating to the development of resistance by androgen-independent tumors are introduced, in terms of the contribution of anoikis and cross-talk of androgens with key growth factor signaling pathways. This volume also provides insightful discussion on the exploitation of the apoptotic and angiogenic synergism towards complete eradication of prostate tumors. Last but not least, it includes reflections on the drug development challenge based on the analysis of data from existing clinical trials.

From the Back Cover

This book focuses on the functional significance of targeting apoptosis for the treatment of prostate cancer. New concepts on the challenges relating to the development of resistance by androgen-independent tumors are introduced, in terms of the contribution of anoikis and cross-talk of androgens with key growth factor signaling pathways. This volume also provides insightful discussion on the exploitation of the apoptotic and angiogenic synergism towards complete eradication of prostate tumors. Last but not least, it includes reflections on the drug development challenge based on analysis of data from existing clinical trials.